CD19 and diffuse large B-cell lymphoma: However, since nearly 25% of anti‐CD19 CAR‐T cell therapy for R/R DLBCL failed due to antigen loss,15 and CAR‐T cell therapy targeting other targets such as CD20 and CD22 has achieved encouraging results,16, 17 we speculated that a combined‐target CAR‐T cell treatment to cover more than one target might potentially increase the efficacy by remedying antigen loss‐associated failure.